MiR-338-3p Enhances Ovarian Cancer Cell Sensitivity to Cisplatin by Downregulating WNT2B
10.3349/ymj.2019.60.12.1146
- Author:
Qin NIU
1
,
2
;
Zhenghong LIU
;
Jia GAO
;
Qiao WANG
Author Information
1. Department of Oncology, The First People's Hospital of Lianyungang, Lianyungang, China. lyg82072010@
2. com
- Publication Type:Original Article
- Keywords:
WNT2B;
miR-338-3p;
ovarian cancer;
chemoresistance
- MeSH:
Apoptosis;
Blotting, Western;
Cisplatin;
Epithelial-Mesenchymal Transition;
Flow Cytometry;
Gene Expression;
Heterografts;
Humans;
In Vitro Techniques;
MicroRNAs;
Ovarian Neoplasms;
Polymerase Chain Reaction;
RNA
- From:Yonsei Medical Journal
2019;60(12):1146-1156
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: Chemoresistance is a concern in ovarian cancer patients, in whom survival remains. MicroRNA, a novel class of small RNAs, have frequently been found to be dysregulated in human malignancies and to act as negative regulators of gene expression. This study aimed to explore the function of miR-338-3p in cisplatin resistance in ovarian cancer and potential molecular mechanisms thereof. MATERIALS AND METHODS: The expression levels of miR-338-3p and WNT2B in ovarian cancer tissues and cells were estimated by real-time quantitative polymerase chain reaction (RT-qPCR). In addition, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazol-3-ium bromide (MTT), transwell, and flow cytometry assays were used to assess biological role of miR-338-3p in vitro. Western blot assay was conducted to measure protein expression of WNT2B, epithelial-mesenchymal transition (EMT)-related proteins, and apoptosis-related proteins. The relationship between miR-338-3p and WNT2B was confirmed by dual-luciferase reporter. Finally, a xenograft tumor model was developed to explore the effects of overexpression of miR-338-3p on tumor growth in ovarian cancer in vivo. RESULTS: MiR-338-3p was downregulated in cisplatin resistant ovarian cancer tissues and cells. Mechanistically, high expression of miR-338-3p enhanced cell sensitivity to cisplatin by inhibiting proliferation, motility, and EMT and by promoting apoptosis via targeting WNT2B expression in vitro. Furthermore, overexpression of miR-338-3p increased cisplatin sensitivity among ovarian cancer in an in vivo xenograft tumor model. CONCLUSION: MiR-338-3p enhances the sensitivity of ovarian cancer cells to cisplatin by downregulating WNT2B.
